Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibits Tumor Growth in Vivo

Experimental Data Snapshot

  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao, Z.F.Hasvold, L.Wang, L.Wang, X.Petros, A.M.Park, C.H.Boghaert, E.R.Catron, N.D.Chen, J.Colman, P.M.Czabotar, P.E.Deshayes, K.Fairbrother, W.J.Flygare, J.A.Hymowitz, S.G.Jin, S.Judge, R.A.Koehler, M.F.Kovar, P.J.Lessene, G.Mitten, M.J.Ndubaku, C.O.Nimmer, P.Purkey, H.E.Oleksijew, A.Phillips, D.C.Sleebs, B.E.Smith, B.J.Smith, M.L.Tahir, S.K.Watson, K.G.Xiao, Y.Xue, J.Zhang, H.Zobel, K.Rosenberg, S.H.Tse, C.Leverson, J.D.Elmore, S.W.Souers, A.J.

(2014) ACS Med Chem Lett 5: 1088-1093

  • DOI: https://doi.org/10.1021/ml5001867
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.

  • Organizational Affiliation

    AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064 United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Bcl-2-like protein 1
A, B
167Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
PHAROS:  Q07817
GTEx:  ENSG00000171552 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07817
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on 3CQ

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid
C35 H32 F N5 O4 S2
Binding Affinity Annotations 
IDSourceBinding Affinity
3CQ Binding MOAD:  4QVX Ki: 1.00e-2 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 73.107α = 90
b = 90.955β = 90
c = 83.736γ = 90
Software Package:
Software NamePurpose
ADSCdata collection
PROCESSdata reduction
PROCESSdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2015-07-22 
  • Deposition Author(s): Park, C.H.

Revision History  (Full details and data files)

  • Version 1.0: 2015-07-22
    Type: Initial release
  • Version 1.1: 2017-07-26
    Changes: Refinement description, Source and taxonomy
  • Version 1.2: 2024-02-28
    Changes: Data collection, Database references, Derived calculations